“Our rapidly growing knowledge of cancer biology combined with technological advances, make this the most promising time for providing patients with new cancer treatment and prevention opportunities. ASCO’s cancer research blueprint report and several abstracts from ASCO’s recent meeting exemplify the potential that molecularly-driven therapies have to transform clinical research. ASCO is pleased to work with the conference organizers to collaborate to advance cancer research and care.” Sandra M. Swain, M.D., ASCO President 2012-2013 and Medstar Washington Hospital Center
“From our roots, more than ten years ago, as the first company developing miRNA research products evolving to our current focus on commercializing diagnostic oncology products, our goal has been to ‘make a dent in cancer.’” Matt Winkler, Ph.D., CEO & CSO, Asuragen, Inc.
“As a leading provider of comprehensive, cancer-diagnostic laboratory services, Clarient is dedicated to enhancing personalized cancer care by translating biomarker discovery to aid the development of new therapeutics and to assist physicians in determining the eligibility of their patients to receive the most appropriate therapy.” Ms. Carrie Eglinton Manner, Chief Executive Officer, Clarient, a GE Healthcare company
“We urgently need better therapies and improved outcomes for brain tumor patients, so we are pleased to be a sponsor of the Turning the Tide Against Cancer conference, the agenda for which correlates to our own organization’s mission and current initiatives. Through approaches such as systems biology, the National Brain Tumor Society is pursuing a goal of personalized cancer care by advocating for and funding targeted, innovative, high-value research, and encouraging other organizations to do the same.” N. Paul TonThat, Executive Director, National Brain Tumor Society
“As our understanding of the biology and genetics of cancer continue to advance, we must work across the boundaries of industry, private enterprise, academia and government to ensure an environment where cutting-edge research is supported and patient access to breakthrough medicines is a priority. At Pfizer, we understand the need for continued innovation in cancer care and have seen the value that a precision approach to drug development can bring to payers, physicians and most of all patients with cancer.” Mace Rothenberg, M.D., Senior Vice President of Clinical Development and Medical Affairs, Pfizer Oncology
“While we still have a long way to go in treating and understanding cancer, we have also made incredible progress. Cancer is an extremely complicated disease that has impacted tens of millions of American lives. The more we learn about it, the more dauntingly complex we realize it is. To move forward, we must band together to find ways to continue to advance care in an era of cost-containment. I am proud to be part of this discussion to seek pathways forward and improve the future for cancer patients.” John J. Castellani, President and CEO, Pharmaceutical Research and Manufacturers of America
Read Additional Voices from the Community